

MAR. 24. 2004 10:37AM

MARSHALL GERSTEIN & BORUN

NO. 4821 P. 1

RECEIVED
CENTRAL FAX CENTER

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

MAR 24 2004

OFFICIAL

March 24, 2004

FACSIMILE TRANSMISSION SHEET

TO

COMPANY USPTO
FAX NO. 1-703-872-9306
PHONE NO.

FROM: Sharon M. Sintich **EXTENSION:** 818
PAGES (INCLUDING THIS PAGE): 12 **CLIENT NO:** 29915
MATTER NO: 6280M
PLEASE CONFIRM RECEIPT: Yes **COUNTRY CODE:** US

MESSAGE:

Please contact Jill L. Schumerth at (312) 474-6818 if you do not receive all of the pages in good condition.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

PTO/SB/21 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/869,414
		Filing Date	June 27, 2001
		First Named Inventor	Mark E. Gurney
		Art Unit	1647
		Examiner Name	C. Nichols
Total Number of Pages in This Submission	1	Attorney Docket Number	29915/6280M

ENCLOSURES (Check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input checked="" type="checkbox"/> Terminal Disclaimer (2)	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MARSHALL, GERSTEIN & BORUN LLP Sharon M. Sintich - 48,484
Signature	
Date	March 24, 2004

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 672-9306, on the date shown below.

Dated: March 24, 2004

Signature: 

(Sharon M. Sintich)

MAR. 24. 2004 10:38AM

MARSHALL GERSTEIN & BORUN

NO. 4821 P. 3

PTO/SB/17 (10-03)

Approved for use through 7/31/2005. OMB 0551-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 400.00)

Complete if Known

Application Number	09/869,414
Filing Date	June 27, 2001
First Named Inventor	Mark E. Gurney
Examiner Name	C. Nichols
Art Unit	1647
Attorney Docket No.	29915/6280M

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None

Deposit Account

Deposit Account Number **13-2855**

Deposit Account Name **MARSHALL, GERSTEIN & BORUN LLP**

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments

Charge any additional fee(s) or any underpayment of fee(s)

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1051	130	2051	65
1052	50	2052	25
1053	130	1053	130
1812	2,520	1812	2,520
1804	820*	1804	820*
1805	1,840*	1805	1,840*
1251	110	2251	55
1252	420	2252	210
1253	950	2253	475
1254	1,480	2254	740
1255	2,010	2255	1,005
1401	330	2401	165
1402	330	2402	165
1403	290	2403	145
1451	1,510	1451	1,510
1452	110	2452	55
1453	1,330	2463	665
1501	1,330	2501	885
1502	480	2502	240
1503	840	2503	320
1460	130	1460	130
1807	50	1807	50
1806	180	1806	180
8021	40	8021	40
1809	770	2809	385
1810	770	2810	385
1801	770	2801	385
1802	900	1802	900
Other fee (specify)		1814	Statutory Disclaimer (2)
			220.00
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$)	400.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	-20** =	<input type="checkbox"/> X	=	Fee Paid
Independent Claims	-3** =	<input type="checkbox"/> X	=	
Multiple Dependent				


Large Entity	Small Entity	Fee Description	
Fee Code	Fee (\$)	Fee Code	
1202	18	2202	9
1201	86	2201	43
1203	280	2203	145
1204	86	2204	43
1205	18	2205	9

SUBTOTAL (2) (\$ 0.00)

** or number previously paid, if greater. For Reissues, see above


SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Sharon M. Sintich	Registration No. (Attorney/Agent)	48,484	Telephone	(312) 474-8631
Signature	 March 24, 2004				


I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-9306, on the date shown below.

Dated: March 24, 2004

Signature:  (Sharon M. Sintich)

I hereby certify that this paper and papers referred to as being attached, are being transmitted via facsimile (Fax No. 703-872-9306) to the Commissioner for Patents, Alexandria VA, 22313, on

Dated: March 24, 2003

Signature: 
(Sharon M. Sintich)

Docket No.: 29915/6280M
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark E. Gurney, et al.

Application No.: 09/869,414

Group Art Unit: 1647

Filed: June 27, 2001

Examiner: C. Nichols

For: ALZHEIMER'S DISEASE SECRETASE, APP
SUBSTRATES THEREFOR, AND USES
THEREFOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The above-identified application is a member of a family of co-pending U.S. applications (the "Asp2" applications). This Information Disclosure Statement describes the family of applications for the Examiner.

I. Prosecution Strategy

A multi-application filing strategy was initiated to expedite prosecution of the Asp2 patent applications. Petitions to make special require restriction to a single invention. It was predicted that the originally filed claims in 09/416,901 would be restricted into at least 5 claim groups (human Asp2 polynucleotides, human Asp2 polypeptides, methods of screening, murine Asp2 polynucleotide and polypeptide sequences, and methods of using antisense oligonucleotides). Therefore, 10 divisional applications were filed in April, 2000 wherein these 5 claim groups were each presented in two divisional applications. Petitions to make special were filed in five of the divisional applications (one for each claim set). Because of antidotal evidence that petitions to make special will sometimes actually slow prosecution, five identical applications were filed without petitions.

Application No.: 09/869,414

The American Inventor's Protection Act of November 29, 2000 created new provisional rights in the United States based on a published application. Therefore, five additional divisional applications were filed in February, 2001 for the purpose of publication in the United States. Since the speed at which the U.S. PTO would publish these applications was uncertain, three PCT applications were filed with the International Bureau with a request for expedited publication in May, 2001. The present application is a national phase application of one of these PCT applications. These steps were taken to have an application publish and be effective in the U.S. for provisional rights as soon as possible.

II. Related Pending Applications

Submitted herewith, as Appendix A and Form PTO-1449, is list of pending U.S. patent applications that are related to the above-identified application. The related applications claim priority to U.S. provisional applications 60/101,594 and 60/155,493, and U.S. application 09/404,133 (abandoned). One or more of the related applications may contain claims that are similar in scope or content to claims of the present application. Copies of these applications are not enclosed, but are pending in the U.S. Patent Office and should be available to the Examiner.

These pending applications are currently under examination by Examiners Sharon Turner, Olga Chernyshev or Elizabeth Slobodyansky. Examiners Turner and Chernyshev, both of whom have examined multiple applications of the family, have been made aware of the size and complexity of the patent family on an informal basis. As this is the present examiner's first exposure to the patent family, this statement is submitted to assist him in understanding the patent family.

The elected claims in the present invention are directed to polynucleotides of SEQ ID NO: 3, the polypeptides (SEQ ID NO: 4) encoded thereby and methods of using these polynucleotides and polypeptides. The following related pending U.S. applications contain claims directed to SEQ ID NO: 3, SEQ ID NO: 4 and/or methods of screening using the polynucleotides or polypeptides: 09/548,368, 09/548,365, 09/548,366, 09/549,369, 09/794,743, 09/794,927, 09/794,847, and 09/794,925.

During the course of prosecution of these applications, different examiners have raised a variety of rejections under 35 U.S.C. §102, §103, §112, first and second paragraphs, and double patenting. Upon request, the Applicants will provide the Examiner

Application No.: 09/869,414


with copies of office actions and/or responses filed for the related applications. The Examiner is invited to contact the undersigned if further explanation of the patent family is necessary.

III. Conclusion

This Supplemental Information Disclosure Statement is being submitted after receipt of the first office action on the merits. Please charge the fee (\$180.00) due under 37 C.F.R. §1.97 (c) to Deposit Account No. 13-2855. The Commissioner is authorized to charge any additional fees due with this Statement to the above-identified Deposit Account.

Dated: March 24, 2004

Respectfully submitted,

By 
Sharon M. Sintich
Registration No.: 43,484
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agents for Applicant